Hu Chao, Shen Meiying, Han Xiaojian, Chen Qian, Li Luo, Chen Siyin, Zhang Jing, Gao Fengxia, Wang Wang, Wang Yingming, Li Tingting, Li Shenglong, Huang Jingjing, Wang Jianwei, Zhu Ju, Chen Dan, Wu Qingchen, Tao Kun, Pang Da, Jin Aishun
Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing 400016, PR China.
Chongqing Key Laboratory of Cancer Immunology Translational Medicine, Chongqing Medical University, Chongqing 400016, PR China.
Genes Dis. 2022 Jan;9(1):216-229. doi: 10.1016/j.gendis.2021.05.006. Epub 2021 Jun 29.
Despite the growing knowledge of T cell responses in COVID-19 patients, there is a lack of detailed characterizations for T cell-antigen interactions and T cell functions. Here, with a predicted peptide library from SARS-CoV-2 S and N proteins, we found that specific CD8 T cell responses were identified in over 75% of COVID-19 convalescent patients (15/20) and an epitope from the N protein, N (KTFPPTEPK), was the most dominant epitope from our selected peptide library. Importantly, we discovered 2 N-specific T cell receptors (TCRs) with high functional avidity that were independent of the CD8 co-receptor. These TCRs exhibited complementary cross-reactivity to several presently reported N mutant variants, as to the wild-type epitope. Further, the natural functions of these TCRs in the cytotoxic immunity against SARS-CoV-2 were determined with dendritic cells (DCs) and the lung organoid model. We found that the N epitope could be normally processed and endogenously presented by these different types of antigen presenting cells, to elicit successful activation and effective cytotoxicity of CD8 T cells . Our study evidenced potential mechanisms of cellular immunity to SARS-CoV-2, and illuminated potential ways of viral clearance in COVID-19 patients. These results indicate that utilizing CD8-independent TCRs against SARS-CoV-2-associated antigens may provide functional superiority that is beneficial for the adoptive cell immunotherapies based on natural or genetically engineered T cells. Additionally, this information is highly relevant for the development of the next-generation vaccines with protections against continuously emerged SARS-CoV-2 mutant strains.
尽管我们对新冠病毒肺炎(COVID-19)患者的T细胞反应的了解日益增多,但对于T细胞与抗原的相互作用以及T细胞功能仍缺乏详细的特征描述。在此,利用来自严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突蛋白(S)和核衣壳蛋白(N)的预测肽库,我们发现在超过75%的COVID-19康复患者(20例中的15例)中鉴定出了特异性CD8 T细胞反应,并且来自N蛋白的一个表位N(KTFPPTEPK)是我们所选肽库中最主要的表位。重要的是,我们发现了2种具有高功能亲和力且不依赖CD8共受体的N特异性T细胞受体(TCR)。这些TCR对几种目前报道的N突变变体以及野生型表位均表现出互补的交叉反应性。此外,利用树突状细胞(DC)和肺类器官模型确定了这些TCR在针对SARS-CoV-2的细胞毒性免疫中的天然功能。我们发现该N表位能够被这些不同类型的抗原呈递细胞正常加工并内源性呈递,从而成功激活CD8 T细胞并产生有效的细胞毒性。我们的研究证明了针对SARS-CoV-2的细胞免疫的潜在机制,并阐明了COVID-19患者中病毒清除的潜在途径。这些结果表明,利用针对SARS-CoV-2相关抗原的不依赖CD8的TCR可能具有功能优势,这有利于基于天然或基因工程T细胞的过继性细胞免疫疗法。此外,这些信息对于开发针对不断出现的SARS-CoV-2突变株具有保护作用的下一代疫苗具有高度相关性。